Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readoutsJul 30Quarterly updateNeurocrine Biosciencesvalbenazine
Palvella Therapeutics adds Matthew Pauls to board of directorsJun 30PeoplePieris Pharmaceuticals, Inc.
Sign inSign in